<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5035">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180777</url>
  </required_header>
  <id_info>
    <org_study_id>CR-1579AP</org_study_id>
    <nct_id>NCT01180777</nct_id>
  </id_info>
  <brief_title>Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP)</brief_title>
  <official_title>Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP) Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the lens fit (mechanical and cosmetic lens fit) of
      the printed etafilcon A with polyvinylpyrrolidone (PVP).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lens Fit Acceptance</measure>
    <time_frame>10-15 minutes post lens fit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lens fit acceptance (whether acceptable or unacceptable) was assessed by the Investigator at dispensing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binocular Snellen Visual Acuity (VA)</measure>
    <time_frame>10-15 minutes post lens fit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Binocular Snellen VA was assessed at dispensing by Investigator using a Snellen vision chart. Subjects were analyzed based on their performance on a Snellen Vision chart exam in the study lenses in an effort to measure how well the lenses perform for vision correction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>After 6-9 days of lens wear</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corneal staining type was graded in a 5-point scale over the 5 corneal regions by Investigator using a slit lamp; 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe. Maximum grade of corneal staining type over the 5 corneal regions was categorized either absence or presence of corneal staining for the analysis.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>etafilcon A (A)/etafilcon A (B)/etafilcon A (C)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A (A)/etafilcon A (C)/etafilcon A (B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A (C)/etafilcon A (A)/etafilcon A (B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A (B)/etafilcon A (C)/etafilcon A (A)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Printed etafilcon A Lens with PVP (B) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A (C)/etafilcon A (B)/etafilcon A (A)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A (B)/etafilcon A (A)/etafilcon A (C)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A (A)</intervention_name>
    <description>Daily wear contact lens</description>
    <arm_group_label>etafilcon A (A)/etafilcon A (B)/etafilcon A (C)</arm_group_label>
    <arm_group_label>etafilcon A (A)/etafilcon A (C)/etafilcon A (B)</arm_group_label>
    <arm_group_label>etafilcon A (C)/etafilcon A (A)/etafilcon A (B)</arm_group_label>
    <arm_group_label>etafilcon A (B)/etafilcon A (C)/etafilcon A (A)</arm_group_label>
    <arm_group_label>etafilcon A (C)/etafilcon A (B)/etafilcon A (A)</arm_group_label>
    <arm_group_label>etafilcon A (B)/etafilcon A (A)/etafilcon A (C)</arm_group_label>
    <other_name>printed etafilcon A Lens with PVP (A)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A (B)</intervention_name>
    <description>Daily wear contact lens</description>
    <arm_group_label>etafilcon A (A)/etafilcon A (B)/etafilcon A (C)</arm_group_label>
    <arm_group_label>etafilcon A (A)/etafilcon A (C)/etafilcon A (B)</arm_group_label>
    <arm_group_label>etafilcon A (C)/etafilcon A (A)/etafilcon A (B)</arm_group_label>
    <arm_group_label>etafilcon A (B)/etafilcon A (C)/etafilcon A (A)</arm_group_label>
    <arm_group_label>etafilcon A (C)/etafilcon A (B)/etafilcon A (A)</arm_group_label>
    <arm_group_label>etafilcon A (B)/etafilcon A (A)/etafilcon A (C)</arm_group_label>
    <other_name>printed etafilcon A Lens PVP (B)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A (C)</intervention_name>
    <description>Daily wear contact lens</description>
    <arm_group_label>etafilcon A (A)/etafilcon A (B)/etafilcon A (C)</arm_group_label>
    <arm_group_label>etafilcon A (A)/etafilcon A (C)/etafilcon A (B)</arm_group_label>
    <arm_group_label>etafilcon A (C)/etafilcon A (A)/etafilcon A (B)</arm_group_label>
    <arm_group_label>etafilcon A (B)/etafilcon A (C)/etafilcon A (A)</arm_group_label>
    <arm_group_label>etafilcon A (C)/etafilcon A (B)/etafilcon A (A)</arm_group_label>
    <arm_group_label>etafilcon A (B)/etafilcon A (A)/etafilcon A (C)</arm_group_label>
    <other_name>printed etafilcon A Lens PVP (C)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must be at least 18 years of age and less than 40 years of age.

          2. The subject must be a light eye Caucasian female habitual soft contact lens wearer.

          3. The subject must be concept acceptors for cosmetic and/or limbal ring lenses. A
             concept screening questionnaire will be used and top 3 box (in 5-point scale) is
             eligible.

          4. The subject must have no known ocular or systemic allergies that might interfere with
             contact lens wear.

          5. The subject must have no known systemic disease, or need for medication, which might
             interfere with contact lens wear.

          6. The subject's optimal vertexed spherical equivalent distance correction must be
             between -1.00 and - 5.00D.

          7. Any cylinder power must be â‰¤ -0.75D.

          8. The subject must have visual acuity best correctable to 20/25+3 or better for each
             eye.

          9. The subject must have normal eyes (no ocular medications or ocular infection of any
             type).

         10. The subject must read and sign the Statement of Informed Consent.

         11. The subject must appear able and willing to adhere to the instructions set forth in
             this clinical protocol.

        Exclusion Criteria:

          1. Ocular or systemic allergies or disease which might interfere with contact lens wear.

          2. Systemic disease or use of medication which might interfere with contact lens wear.

          3. Clinically significant (grade 3 or worse) corneal edema, corneal vascularization,
             corneal staining, or any other abnormalities of the cornea which would contraindicate
             contact lens wear.

          4. Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which
             might interfere with contact lens wear.

          5. Any ocular infection.

          6. Any corneal distortion resulting from previous hard or rigid gas permeable contact
             lens wear.

          7. Any color deficiencies - to the best of the subject's knowledge.

          8. Pregnancy or lactation.

          9. Diabetes.

         10. Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease
             (e.g. HIV).

         11. Habitual contact lens type is toric, multifocal, or is worn as extended wear.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Cupertino</city>
        <state>California</state>
        <zip>95014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 6, 2015</lastchanged_date>
  <firstreceived_date>August 3, 2010</firstreceived_date>
  <firstreceived_results_date>November 13, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was an eight-site, randomized, 4-visit, bilateral crossover, dispensing trial.</recruitment_details>
      <pre_assignment_details>Of those 95 enrolled subjects in this study, 3 did not meet the eligibility criteria, 6 prematurely discontinued from the study, and 6 excluded from the analysis due to protocol deviations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>All subjects who enrolled, randomized, and exposed to the study lenses. Subjects where randomized to a study arm and wore all three of the study lenses by study completion. Randomization was to the arms as outlined in the 'arms' section of the protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor lens fit</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Subjects were to wear all three lenses over the course of the study.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="95"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="95"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="95"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lens Fit Acceptance</title>
        <description>Lens fit acceptance (whether acceptable or unacceptable) was assessed by the Investigator at dispensing.</description>
        <time_frame>10-15 minutes post lens fit</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who successfully completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A (A)</title>
            <description>Daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A (B)</title>
            <description>Daily wear contact lens</description>
          </group>
          <group group_id="O3">
            <title>Etafilcon A (C)</title>
            <description>Daily wear contact lens</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="80"/>
                  <measurement group_id="O3" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes analyzed</title>
            <units>Eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="160"/>
                  <measurement group_id="O3" value="157"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Lens Fit Acceptance</title>
            <description>Lens fit acceptance (whether acceptable or unacceptable) was assessed by the Investigator at dispensing.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Acceptable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="158"/>
                  <measurement group_id="O3" value="157"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unacceptable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Binocular Snellen Visual Acuity (VA)</title>
        <description>Binocular Snellen VA was assessed at dispensing by Investigator using a Snellen vision chart. Subjects were analyzed based on their performance on a Snellen Vision chart exam in the study lenses in an effort to measure how well the lenses perform for vision correction.</description>
        <time_frame>10-15 minutes post lens fit</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who successfully completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A (A)</title>
            <description>Daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A (B)</title>
            <description>Daily wear contact lens</description>
          </group>
          <group group_id="O3">
            <title>Etafilcon A (C)</title>
            <description>Daily wear contact lens</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="78"/>
                  <measurement group_id="O2" value="78"/>
                  <measurement group_id="O3" value="78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Binocular Snellen Visual Acuity (VA)</title>
            <description>Binocular Snellen VA was assessed at dispensing by Investigator using a Snellen vision chart. Subjects were analyzed based on their performance on a Snellen Vision chart exam in the study lenses in an effort to measure how well the lenses perform for vision correction.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>20/15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>20/20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Staining</title>
        <description>Corneal staining type was graded in a 5-point scale over the 5 corneal regions by Investigator using a slit lamp; 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe. Maximum grade of corneal staining type over the 5 corneal regions was categorized either absence or presence of corneal staining for the analysis.</description>
        <time_frame>After 6-9 days of lens wear</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who successfully completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A (A)</title>
            <description>Daily wear contact lens</description>
          </group>
          <group group_id="O2">
            <title>Etafilcon A (B)</title>
            <description>Daily wear contact lens</description>
          </group>
          <group group_id="O3">
            <title>Etafilcon A (C)</title>
            <description>Daily wear contact lens</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="80"/>
                  <measurement group_id="O3" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eye analyzed</title>
            <units>eye</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="160"/>
                  <measurement group_id="O2" value="154"/>
                  <measurement group_id="O3" value="158"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Corneal Staining</title>
            <description>Corneal staining type was graded in a 5-point scale over the 5 corneal regions by Investigator using a slit lamp; 0=none, 1=trace, 2=mild, 3=moderate, and 4=severe. Maximum grade of corneal staining type over the 5 corneal regions was categorized either absence or presence of corneal staining for the analysis.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Central region grade &gt; 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Inferior region grade &gt; 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasal region grade &gt; 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Superior region grade &gt; 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Temporal region grade &gt; 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>Subjects were to wear all three lenses over the course of the study. Due to the non-ocular related AE, all subjects are summarized to report the occurrence of event.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication requires agreement and written authorization from the Sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael S. Mayers, O.D., FAAO</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care</organization>
      <phone>1-904-443-3252</phone>
      <email>MMayers@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
